| Amy A Werner, NP | |
|
225 Williamson St, Elizabeth, NJ 07202-3625 | |
| (732) 539-8280 | |
| Not Available |
| Full Name | Amy A Werner |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 225 Williamson St, Elizabeth, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770048522 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 26NR14740300 (New Jersey) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 26NJ00901500 (New Jersey) | Primary |
| Entity Name | Trinitas Physicians Practice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205189941 PECOS PAC ID: 6709002850 Enrollment ID: O20140725000027 |
News Archive
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.
Six of the top research centres in Catalonia have taken a step forward in their collaboration by setting up The Barcelona Institute of Science and Technology. The centres involved are: the Centre for Genomic Regulation; the Institute of Chemical Research of Catalonia; the Catalan Institute for Nanoscience and Nanotechnology; the Institute of Photonic Sciences; the High Energy Physics Institute; and the Institute for Research in Biomedicine.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2011 (3Q11) of $2.67, compared to $2.32 per share for the quarter ended September 30, 2010.
A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.
TRU-D SmartUVC LLC will feature its Ebola-killing UVC automated disinfection robot at IDWeek 2014 in Philadelphia this week from October 8 to 12 at booth 826.
› Verified 6 days ago
| Entity Name | Hospitalist Physicians Of New Jersey Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588021851 PECOS PAC ID: 3476859927 Enrollment ID: O20160309000541 |
News Archive
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.
Six of the top research centres in Catalonia have taken a step forward in their collaboration by setting up The Barcelona Institute of Science and Technology. The centres involved are: the Centre for Genomic Regulation; the Institute of Chemical Research of Catalonia; the Catalan Institute for Nanoscience and Nanotechnology; the Institute of Photonic Sciences; the High Energy Physics Institute; and the Institute for Research in Biomedicine.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2011 (3Q11) of $2.67, compared to $2.32 per share for the quarter ended September 30, 2010.
A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.
TRU-D SmartUVC LLC will feature its Ebola-killing UVC automated disinfection robot at IDWeek 2014 in Philadelphia this week from October 8 to 12 at booth 826.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy A Werner, NP 601 Laurel St, Bayville, NJ 08721-2221 Ph: (732) 539-8280 | Amy A Werner, NP 225 Williamson St, Elizabeth, NJ 07202-3625 Ph: (732) 539-8280 |
News Archive
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.
Six of the top research centres in Catalonia have taken a step forward in their collaboration by setting up The Barcelona Institute of Science and Technology. The centres involved are: the Centre for Genomic Regulation; the Institute of Chemical Research of Catalonia; the Catalan Institute for Nanoscience and Nanotechnology; the Institute of Photonic Sciences; the High Energy Physics Institute; and the Institute for Research in Biomedicine.
Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2011 (3Q11) of $2.67, compared to $2.32 per share for the quarter ended September 30, 2010.
A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.
TRU-D SmartUVC LLC will feature its Ebola-killing UVC automated disinfection robot at IDWeek 2014 in Philadelphia this week from October 8 to 12 at booth 826.
› Verified 6 days ago
Priscilla Maranon, ANP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 216 Palmer St, Elizabeth, NJ 07202 Phone: 908-352-2656 | |
Vijayeta Dripaul, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 32 Oakwood Pl, Elizabeth, NJ 07208 Phone: 908-208-9099 | |
Virginia Guanco-villanueva, A.P.N. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 240 Williamson St, Suite 403, Elizabeth, NJ 07202 Phone: 908-289-6996 | |
Novil Kaur, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 240 Williamson St Ste 305, Elizabeth, NJ 07202 Phone: 908-354-5353 | |
Mirleivis D Sanchez Ruiz, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 935 Cross Ave, Elizabeth, NJ 07208 Phone: 551-556-8691 | |
Tony Malek, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1150 Dickinson St, Elizabeth, NJ 07201 Phone: 201-522-4009 | |
Kacy Eunkyung In, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 817 Rahway Ave, Elizabeth, Elizabeth, NJ 07202 Phone: 908-353-5750 |